Chanan-Khan Asher 4

What Happened

• Asher Chanan-Khan, a director of Cellectar Biosciences (CLRB), received a grant of 25,000 derivative shares on July 7, 2026. The reported acquisition price is $0.00, and the filing classifies the transaction as a grant/award (derivative security), not an open-market purchase or sale.

Key Details

• Transaction date: 2026-07-07; Form 4 filed: 2026-07-08 (timely filing).
• Transaction type/code: Grant/Award (A) of derivative securities.
• Quantity and price: 25,000 derivative shares; acquisition price reported $0.00.
• Vesting: The award “shall vest in full on July 7, 2027,” subject to continued service (footnote F1).
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Tax withholding / cashless exercise: Not indicated in the filing excerpt.

Context

• This was a compensation-related grant of derivative securities (e.g., options or RSUs), which typically vests over time and is distinct from an open-market purchase or sale. Such grants are routine for directors and reflect compensation, not an immediate market bet; the award vests in one year if the director remains in service.